Triazole derivatives of structural formula I are selective inhibitors of
the 11.beta.-hydroxysteroid dehydrogenase-1. The compounds are useful for
the treatment of diabetes, such as noninsulin-dependent diabetes (NIDDM),
hyperglycemia, obesity, insulin resistance, dyslipidemia, hyperlipidemia,
hypertension, Metabolic Syndrome, and other symptoms associated with
NIDDM.
